CASTLE-ZS-04NCT07829874
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 20, 2026 to Oct 26, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: 24 months
Secondary (7)
Disease control rate (DCR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1
Duration of Response (DOR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1
Time to Response (TTR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1
Progression Free Survival (PFS) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1
Overall survival (OS) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1
Show 2 moreShow less
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Translational study
Arms and interventions
ICC-01Experimental
Intrahepatic cholangiocarcinoma (ICC) received QL1706 + lenvatinib
ICC-02Experimental
Intrahepatic cholangiocarcinoma (ICC) received QL1706 + lenvatinib+cryoablation
ECC-01Experimental
Extrahepatic cholangiocarcinoma (ECC) received QL1706 + lenvatinib
ECC-02Experimental
Extrahepatic cholangiocarcinoma (ECC) received QL1706 + lenvatinib +cryoablation
GBC-01Experimental
Gallbladder cancer (GBC) received QL1706 + lenvatinib
GBC-02Experimental
Gallbladder cancer (GBC) received QL1706 + lenvatinib+cryoablation
Drugs: QL1706 (Iparomlimab/Tuvonralimab), Lenvatinib
Procedures: Cryoablation
Sites
1 site in 1 country
- Zhongshan Hospital, Fudan UniversityShanghai, Shanghai Municipality, China